[Click eStock] "DoubleWSI, Quantum Jump Expected Through M&A and New Business"

KB Securities analyzed on the 11th that DoubleWSI is expected to make a quantum jump through mergers and acquisitions (M&A) and new businesses. No investment opinion or target price was provided.

DoubleWSI was established in 2016 as a medical distribution platform. Leveraging the sales expertise and personal network of spine specialists from Wooridul Hospital, it imports and distributes pharmaceuticals and medical devices for spinal diseases.

Hyunkyum Kim, a researcher at KB Securities, said, "Attention should be paid to DoubleWSI, which is diversifying its business from the existing pharmaceutical distribution centered on hemostatic agents and blood substitutes related to spinal surgery to pharmaceutical manufacturing and surgical robots."

He explained, "They acquired IntroBioPharma, which has strengths in the circulatory and metabolic disease fields. The synergy of the business utilizing the network of about 400 hospitals and clinics that DoubleWSI already possesses is expected to be strong."

He also emphasized the importance of its subsidiary. "Attention should be paid to the subsidiary EasyMediBot. Recently, it signed an MOU for a surgical robot solution partnership with Doosan Robotics," he said. "Starting with supplying collaborative robots for the obstetrics and gynecology surgical assist robot ‘Ubot’ currently under development, the scope of cooperation is expected to expand to brain nerve and cardiovascular medical robots."

He also highlighted the new business in cardiovascular interventional medical devices. DoubleWSI recently signed a domestic general agency contract and began sales for catheter products such as PICC (peripherally inserted central catheter) with UK-based Kimal. Additionally, it signed an exclusive domestic supply contract for Kona-MF and Ancora from China’s Shengjian Tech.

He explained, "With the recent increase in the incidence of cardiovascular diseases due to population aging, the demand for non-surgical treatment methods such as interventional procedures is expanding, and the related market is rapidly growing. It is judged to be the optimal medical device to target the rapidly growing domestic cardiovascular market and is expected to be a significant growth driver in the mid to long term."

This content was produced with the assistance of AI translation services.